Volcano gets to Crux of $300m peripheral embolism market with $36m acquisition
This article was originally published in Clinica
Executive Summary
Volcano, which specialises in devices for facilitating endovascular procedures, has entered the peripheral vascular market by agreeing to acquire privately-held Crux Biomedical for $36 million in cash. Volcano (San Diego, California) will also pay up to $3.1 million in transaction expenses, and a milestone payment of $3.0 million upon US FDA clearance of a 510(k) application submitted by Volcano on or before June 30 2013, for a retrieval device currently being developed by Crux.